Last reviewed · How we verify
Adaptive autologous cell immunotherapy — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Adaptive autologous cell immunotherapy (Adaptive autologous cell immunotherapy) — Assistance Publique - Hôpitaux de Paris.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Adaptive autologous cell immunotherapy TARGET | Adaptive autologous cell immunotherapy | Assistance Publique - Hôpitaux de Paris | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Adaptive autologous cell immunotherapy CI watch — RSS
- Adaptive autologous cell immunotherapy CI watch — Atom
- Adaptive autologous cell immunotherapy CI watch — JSON
- Adaptive autologous cell immunotherapy alone — RSS
Cite this brief
Drug Landscape (2026). Adaptive autologous cell immunotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/adaptive-autologous-cell-immunotherapy. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab